BeOne Medicines Ltd.
ONC evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $40.03B
- Lead Asset:
- brukinsa (Approved)
What it means
What to watch
Prepared research question
What matters most for ONC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ONC
BeOne Medicines Ltd. (ONC) is a global oncology company focused on developing and commercializing innovative cancer therapies, with a leading BTK inhibitor franchise and a deep pipeline spanning hematologic malignancies and solid tumors.
Key risk: Revenue concentration
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 85 clinical trials · 2 catalysts · 3 FDA decisions for BeOne Medicines Ltd..
BeOne Medicines Ltd. (ONC) is a global oncology company focused on developing and commercializing innovative cancer therapies, with a leading BTK inhibitor franchise and a deep pipeline spanning hematologic malignancies and solid tumors.
- Cash & equivalents of $5,098.0M as of 2026-06-30 [sec].
- Total revenue of $1,705.1M and net income of $237.0M as of 2026-06-30 [sec].
- BRUKINSA (zanubrutinib) generated $3.9 billion in global revenues in 2025 and is the global revenue leader in the BTKi class [sec · filed 2026-04-28].
- Sonrotoclax achieved its first global regulatory approval in late 2025, with U.S. FDA action on an NDA for R/R MCL expected in H1 2026 [sec · filed 2026-04-28].
- More than two million patients have been treated with BeOne medicines, and the company employs nearly 12,000 colleagues across six continents [sec · filed 2026-04-28].
What works
- Strong balance sheet with >$4B cash and GAAP profitability achieved in 2025, providing capital for growth and business development [sec · filed 2026-04-28].
- BRUKINSA is the global revenue leader in the BTKi class with $3.9B in 2025 revenues and maintains U.S. new patient share lead [sec · filed 2026-04-28].
- Deep pipeline with multiple late-stage assets (sonrotoclax, BTK CDAC, CDK4i) and proof-of-concept achievements in solid tumor and immunology programs [sec · filed 2026-04-28].
- Patent litigation resolved favorably: USPTO final written decision invalidated all claims of Pharmacyclics US-803 patent, with no damages [sec · filed 2026-04-28].
What to weigh
- Reliance on a single blockbuster drug (BRUKINSA) for the majority of revenue, with pipeline assets still in clinical development [sec · filed 2026-04-28].
- Sonrotoclax and BTK CDAC face competitive pressure from established BTK inhibitors and novel agents in CLL/SLL [sec · filed 2026-04-28].
- Solid tumor portfolio is early-stage with most programs in proof-of-concept or Phase 1/2, with no approved solid tumor drug yet [sec · filed 2026-04-28].
- Redomiciliation to Switzerland from Cayman Islands may introduce regulatory and tax complexities [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
Cash position and profitability
“cash flow remains positive with balance sheet strengthened to >$4B cash”
SEC filings · April 28, 2026
BRUKINSA revenue leadership
“BRUKINSA ® (zanubrutinib), our foundational best-in-class BTK inhibitor that is now approved in more than 75 markets, rapidly emerged as the global revenue leader in the class with $3.9 billion in global revenues in 2025”
SEC filings · April 28, 2026
Sonrotoclax regulatory milestone
“Sonrotoclax, a potentially best-in-class therapy, achieved its first global regulatory approval in late 2025, and we anticipate U.S. FDA regulatory action on a New Drug Application for the treatment of relapsed or refractory mantle cell lymphoma in the first half of 2026”
SEC filings · April 28, 2026
Patent litigation resolution
“Announced USPTO Final Written Decision invalidating all claims of Pharmacyclics US-803 patent; fully resolved the U.S. BRUKINSA patent infringement lawsuit with no damages”
SEC filings · April 28, 2026
Catalyst timeline
- 2026-10-15 · Phase1_Start: Sonrotoclax hepatic impairment study — A Phase 1, open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of sonrotoclax in participants with severe hepatic impairment.
- 2026-10-22 · Phase1_Start: Tacabrutideg hepatic impairment study — A Phase 1, open-label, parallel-group, single-dose study to evaluate safety, tolerability, and pharmacokinetics of tacabrutideg in participants with moderate and severe hepatic impairment.
Risks & what to watch (3)›
Key risks
- Revenue concentration — Heavy reliance on BRUKINSA for revenue; pipeline assets not yet commercialized [sec · filed 2026-04-28].
- Pipeline execution risk — Solid tumor and immunology programs are early-stage; no approved solid tumor drug [sec · filed 2026-04-28].
- Competitive pressure in CLL — Sonrotoclax and BTK CDAC face competition from approved BTK inhibitors and novel agents [sec · filed 2026-04-28].
What to watch
- U.S. FDA decision on sonrotoclax NDA for R/R MCL expected in H1 2026 [sec · filed 2026-04-28].
- Initiation of Phase 3 CDK4i study in first-line HR+/HER2- metastatic breast cancer in H1 2026 [sec · filed 2026-04-28].
- Phase 1 start for sonrotoclax in hepatic impairment on 2026-10-15 [catalyst].
- Phase 1 start for tacabrutideg in hepatic impairment on 2026-10-22 [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run BeOne Medicines Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BeOne Medicines Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.77 · 4% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~1d
0 buys · 130 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
279
Total value held
$10.15B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 8,799,053 | $2.61B |
| primecap management co/ca/ | 4,975,181 | $1.48B |
| capital international investors | 4,158,726 | $1.23B |
| fmr llc | 3,693,610 | $1.10B |
| capital world investors | 1,622,687 | $481.9M |
| hhlr advisors, ltd. | 1,034,306 | $307.2M |
| citadel advisors llc | 1,032,298 | $306.6M |
| temasek holdings (private) ltd | 862,643 | $256.2M |
| blackrock, inc. | 657,501 | $195.3M |
| siren, l.l.c. | 465,000 | $138.1M |
Showing top 10 of 279 institutional holders of BeOne Medicines Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 1.5%
- Days to cover
- 5.4
- Shares short
- 1,154,033
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ONC short interestGovernance
Frequently asked questions
What is the AI investment thesis for BeOne Medicines Ltd.?
BeOne Medicines Ltd. (ONC) is a global oncology company focused on developing and commercializing innovative cancer therapies, with a leading BTK inhibitor franchise and a deep pipeline spanning hematologic malignancies and solid tumors.
What is BeOne Medicines Ltd.'s lead drug candidate?
BeOne Medicines Ltd.'s most advanced tracked candidate is brukinsa (Approved).
What is BeOne Medicines Ltd.'s next catalyst?
BeOne Medicines Ltd.'s next tracked catalyst is a Phase1_Start event — "Phase1_Start: A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment" — expected October 15, 2026.
Who is the CEO of BeOne Medicines Ltd.?
Mr. John V. Oyler is the chief executive officer of BeOne Medicines Ltd. (ONC).
Where is BeOne Medicines Ltd. headquartered?
BeOne Medicines Ltd. (ONC) is headquartered in Basel, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.